Bruton tyrosine kinase (Btk) is a member of the Tec family kinases with a well-characterized role in B-cell antigen receptor (BCR)-signaling and B-cell activation.Btk is a new target for diseases with abnormal B cell activity because it is essential for B cell development and activation through the BCR signaling pathway. The human primary immune deficiency disease X-linked agammaglobulinemia (XLA), which is caused by a mutation in the Btk gene, highlights the importance of Btk, a kinase that is only expressed in B cells and myeloid cells. The BCR signaling pathway depends on Btk in many ways.B cell receptor oligomerization, Syk and Lyn kinase activation, and Btk kinase activation are all caused by antigen binding to the BCR. When Btk is activated, it joins forces with proteins like BLNK, Lyn, and Syk to form a signaling complex that phosphorylates phospholipase C (PLC)2. This results in transcriptional changes that promote B cell survival, proliferation, and/or differentiation by releasing intracellular Ca2+ stores downstream and propagating the BCR signaling pathway through extracellular signal-regulated kinase and NF-B signaling.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
v2306 | BTK inhibitor 17 | 1858206-76-4 | BTK inhibitor 17 is a potent, orally bioactive, irreversible BTK inhibitor (antagonist) with IC50 of 2.1 nM. |
|
V77181 | BTK inhibitor 18 | BTK inhibitor 18 is a specific, orally bioactive, covalent Btk inhibitor (antagonist) with IC50 of 142 nM. | |
|
V69697 | BTK inhibitor 19 | 2557174-19-1 | BTK inhibitor 19 is a selective covalent/irreversible inhibitor of BTK (IC50 = 2.7 nM). |
|
V69687 | BTK-IN-15 | 2820426-92-2 | BTK-IN-15 is a novel Bruton's tyrosine kinase (BTK) inhibitor (antagonist) with good oral activity. |
|
V69675 | BTK-IN-16 | 2883232-92-4 | BTK-IN-16 is an inhibitor (blocker/antagonist) of the BTK wild type and C481S mutant of Bruton's tyrosine kinase (BTK), with IC50s of 5.1 and 4.1 μM respectively. |
|
V78823 | BTK-IN-17 | BTK-IN-17 (compound 36R) is a selective BTK inhibitor (antagonist) with IC50 of 13.7 nM. | |
|
V69690 | BTK-IN-18 | 1374239-71-0 | BTK-IN-18 is a potent, reversible BTK inhibitor (antagonist) with IC50 of 0.002 µM. |
|
V69692 | BTK-IN-19 | 1374240-01-3 | BTK-IN-19 (Compound 51) is a reversible BTK inhibitor (antagonist) with IC50 <0.001 μM. |
|
V69696 | BTK-IN-20 | 1581714-50-2 | BTK-IN-20 (compound 283) is a BTK tyrosine kinase inhibitor and 1H-pyrazolo[3,4-d]pyrimidine analogue. |
|
V69688 | BTK-IN-22 | 2573048-10-7 | BTK-IN-22 is a BTK inhibitor (IC50= 12.8 nM). |
|
V69695 | BTK-IN-23 | 2573048-11-8 | BTK-IN-23 is a BTK inhibitor (IC50= 12.8 nM). |
|
V69701 | BTK-IN-25 | 2562351-92-0 | BTK-IN-25 (compound 71) is a potent BTK inhibitor against BTK(C481S) with IC50 of 0.77 nM. |
|
V69676 | BTK-IN-26 | 2762043-61-6 | BTK-IN-26 (compound 18) is a potent inhibitor of Bruton's tyrosine kinase (BTK) and its C481 mutant, with IC50s of 0.7 and 0.8 nM for BTK and BTK C481S, respectively. |
|
V69693 | BTK-IN-27 | 1841502-36-0 | BTK-IN-27 (example 8) is a BTK inhibitor (IC50= 0.2 nM). |
|
V79868 | BTK-IN-28 | BTK-IN-28 (compound PID-4) is a potent BTK inhibitor (antagonist) with anti-cancer activity. | |
|
V69674 | BTK-IN-5 | 2145152-06-1 | BTK-IN-5 is a covalent BTK inhibitor used to study diseases like cardiovascular disease, respiratory disease, inflammation and diabetes. |
|
V69677 | BTK-IN-6 | 2662512-08-3 | BTK-IN-6 is a potent inhibitor of Bruton's tyrosine kinase (BTK). |
|
V69699 | BTK-IN-8 | 2824922-28-1 | BTK-IN-8 is a potent and specific peripheral covalent BTK inhibitor (IC50=0.22 nM; Kd=0.91 nM). |
|
V69686 | BTKligand 1 | 330785-90-5 | BTK ligand 1 (Compound 1) is a ligand targeting Bruton's tyrosine kinase (Btk). |
|
V69655 | Cinsebrutinib | 2724962-58-5 | Cinsebrutinib is a Bruton's tyrosine kinase inhibitor disclosed in patent number WO2021207549 (compound 5-6). |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
